Treatment of refractory substance-induced psychosis in adolescent males with a genetic predisposition to mental illness

International Journal of Adolescent Medicine and Health

Volumn 26, Issue 2, 2014, Pages 297-301

  Rahmani, Mariam ^a   Paul, Sean ^a   Nguyen, Mathew L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

adolescent; cannabis; clozapine; psychosis; schizophrenia; spice (synthetic cannabinoid)

Indexed keywords

CANNABIS; CHLORPROMAZINE; CLONAZEPAM; CLOZAPINE; DOCUSATE SODIUM; HALOPERIDOL; INORGANIC SALT; LORAZEPAM; MACROGOL; METOPROLOL; OXYCODONE; PSILOCYBINE; RISPERIDONE; VALPROIC ACID;

ADOLESCENT; ADOLESCENT DISEASE; AGGRESSION; AGITATION; AGRANULOCYTOSIS; ALCOHOLISM; ANXIETY; ARTICLE; AUDITORY HALLUCINATION; BEDTIME DOSAGE; CANNABIS SMOKING; CANNABIS USE; CASE REPORT; CAUCASIAN; COMPRESSION FRACTURE; CONSTIPATION; DELUSION; DEPRESSION; DISORIENTATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; EVENING DOSAGE; GENETIC PREDISPOSITION; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MEDICAL HISTORY; MEDICATION COMPLIANCE; MENTAL DISEASE; MENTAL HOSPITAL; MENTAL INSTABILITY; MORNING DOSAGE; MUSHROOM; NEUTROPHIL COUNT; PARANOIA; PSYCHIATRIC DEPARTMENT; PSYCHOMOTOR RETARDATION; PSYCHOSIS; PULSE PRESSURE; REFRACTORY SUBSTANCE INDUCED PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SPICE; SUBSTANCE USE; SUICIDE; SUICIDE ATTEMPT; TACHYCARDIA; TREATMENT DURATION; VISUAL HALLUCINATION;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MARIJUANA SMOKING; PSYCHOSES, SUBSTANCE-INDUCED;

EID: 84899821133     PISSN: 03340139     EISSN: 21910278     Source Type: Journal    
DOI: 10.1515/ijamh-2013-0505     Document Type: Article

References (32)

1. Dulcan MK. Dulcan's textbook of child and adolescent psychiatry. Arlington, VA: American Psychiatric Publishing, Inc., 2010.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed., text rev. Washington, DC: American Psychiatric Association, 2000.
3. Minzenberg MJ, Yoon JH, Carter CS. Schizophrenia. In: Hales RE, Yudofsky SC, Gabbard GO, editors. The American psychiatric publishing textbook of psychiatry, 5th ed. Arlington, VA: American Psychiatric Publishing Inc., 2008.
4. Loranger AW. Sex difference in age at onset of schizophrenia. Archives of general psychiatry 1984;41:157-61.
5. Anderson KK, Fuhrer R, Abrahamowicz M, Malla AK. The incidence of first-episode schizophrenia-spectrum psychosis in adolescents and young adults in Montreal: an estimate from an administrative claims database. Can J Psychiatry 2012;57: 626-33.
6. Cantor-Graae E, Nordström LG, McNeil TF. Substance abuse in schizophrenia: a review of the literature and a study of correlates in Sweden. Schizophr Res 2001;48:69-82.
7. Gershman JA, Fass AD. Synthetic cathinones ("bath salts"): legal and health care challenges. P & T: A Peer Reviewed Journal for Formulary Management 2012;37:571-95.
8. Joksovic P, Mellos N, van Wattum PJ, Chiles C. Bath saltsinduced psychosis and serotonin toxicity. J Clin Psychiatry 2012;73:1125.
9. Jerry J, Collins G, Streem D. Synthetic legal intoxicating drugs: the emerging "incense" and "bath salt" phenomenon. Clev Clin J Med 2012;79:258-64.
10. Striebel JM, Pierre JM. Acute psychotic sequelae of "bath salts". Schizophr Res 2011;133:259-60.
11. Andréasson S, Allebeck P, Engström A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987;ii:1483-6.
12. Bugra H, Rapp C, Studerus E, Aston J, Borgwardt S, et al. Can cannabis use increase the risk for schizophrenic psychoses? Fortschr Neurol Psyc 2012;80:635-43.
13. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depen 2011;117:152-7.
14. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007;370:319-28.
15. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. Brit Med J 2002;325:1199.
16. Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, et al. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Brit Med J 2002;325:1212-3.
17. Power BD, Dragovic M, Jablensky A, Stefanis NC. Does accumulating exposure to illicit drugs bring forward the age at onset in schizophrenia? Aust NZ J Psychiatry 2013;47:51-8.
18. Galvez-Buccollini JA, Proal AC, Tomaselli V, Trachtenberg M, Coconcea C, et al. Association between age at onset of psychosis and age at onset of cannabis use in non-affective psychosis. Schizophr Res 2012;139:157-60.
19. FDA. FDA approves risperdal for two psychiatric conditions in children and adolescents. FDA news release 2007. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/2007/ucm108969.htm 20
20. Fischer-Cornelssen KA, Ferner UJ. An example of European multicenter trials: multispectral analysis of clozapine. Psychopharmacol Bull 1976;12:34-9.
21. Honigfeld G, Patin J, Singer J. Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Adv Ther 1984;1:77-97.
22. Shopsin B, Klein H, Aaronsom M, Collora M. Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison. Arch Gen Psychiatry 1979;36:657-64.
23. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96.
24. Cianchetti C, Ledda MG. Effectiveness and safety of antipsychotics in early onset psychoses: a long-term comparison. Psychiatry Res 2011;189:349-56.
25. Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. J Clin Psychopharm 2012;32:309-16.
26. Bachmann CJ, Gebhardt S, Lehr D, Haberhausen M, Kaiser C, et al. Subjective and biological weight-related parameters in adolescents and young adults with schizophrenia spectrum disorder under clozapine or olanzapine treatment. Z Kinder Jug-Psych 2012;40:151-9.
27. Maayan L, Correll CU. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. J Child Adol Psychop 2011;21:517-35.
28. Wehmeier PM, Heiser P, Remschmidt H. Pancreatitis followed by pericardial effusion in an adolescent treated with clozapine. J Clin Psychopharm 2003;23:102-3.
29. Markovic J, Momcilov-Popin T, Mitrovic D, Ivanovic-Kovacevic S, Sekuli S, et al. Clozapine-induced pericarditis. Afr J Psychiatry (Johannesbg) 2011;14:236-8.
30. Layland JJ, Liew D, Prior DL. Clozapine-induced cardiotoxicity: a clinical update. Med J Australia 2009;190:190-2.
31. Raju P, Rao GK, Davis G. Pericardial effusion in patients with schizophrenia: are they on clozapine? Emerg Med J 2008;25:383-4.
32. Marder SR, Wirshing DA. Chapter 28. Clozapine. In: Schattzberg AF, Nemeroff CB, editors. Textbook of Psychopharmacology, 4th ed. Arlington, VA: American Psychiatric Publishing, 2009